We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Seegene

Download Mobile App





AACC’s Disruptive Technology Award to Highlight Developers of AI and ML Technologies Advancing Medicine and Pathology

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Illustration
Illustration
Three finalists will compete live at the Disruptive Technology Award session at the 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting and a winner will be selected and announced at the conclusion of the session.

AACC's Disruptive Technology Award Competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges. The 2021 Disruptive Technology Award finalists and their disruptive technologies include Day Zero Diagnostics, Inc. — DZD OneSeq Dx; Mammoth Biosciences — DETECTR; and MeMed — MeMed COVID-19 Severity.

The first finalist, Day Zero Diagnostics has developed a set of breakthrough capabilities that can provide a complete diagnosis of bloodstream infections and sepsis, including both the species ID and antibiotic susceptibility profile, in hours vs. days. Its technology enables the unprecedented recovery of pathogen whole genome sequences directly from clinical samples that may contain up to a billion times more human DNA. The company’s algorithms then interpret the genomic data to provide accurate, comprehensive organism ID and antibiotic susceptibility profiles. Day Zero Diagnostics enables a targeted treatment on day zero of hospital admission, resulting in better patient outcomes and cost savings.

The second finalist, Mammoth Biosciences has catalyzed a new approach to molecular diagnostics, called DETECTR. Based on CRISPR, this programmable platform acts as a search engine for biology and is capable of finding and identifying any nucleic acid sequence in the genome. Using proprietary technology licensed exclusively from the University of California, Berkeley and developed internally, Mammoth is working on multiple form factors and test targets from infectious diseases to cancer. For example, DETECTR was configured in less than two weeks to detect SARS-CoV-2, demonstrating the platform’s ability to be quickly tailored to identify any DNA or RNA target. The resulting product, DETECTR BOOST, is a reagent kit that when combined with standard laboratory automation provides labs with unparalleled high throughput molecular testing.

The third finalist, MeMed BV’s lead product accurately differentiates bacterial from viral (BV) infection, enabling improved patient management, including appropriate antibiotic use, in order to help address the global healthcare challenge of antimicrobial resistance. Based on computational integration of bacterial and viral-responsive immune proteins, Key delivers the BV result in 15 minutes from serum. This test was clinically validated on thousands of patients, is CE-marked and 510(k) pending.

The three finalists will present data on their technology in a special session during the Annual Scientific Meeting. During this session, a panel of expert judges will evaluate all presented testing solutions based on feasibility and performance. The audience will also vote for their favorite technology.

Related Links:
American Association for Clinical Chemistry

New
Gold Supplier
SARS-CoV-2/Flu A/B & RSV Test
RespiBio Panel 3 (RBRP3)
New
Decapping, Recapping, Sorting Solution
DC/RC 900 Flex
New
Modular Syndromic Testing System
QIAstat-Dx (DiagCORE) Analyzer
New
High Throughput Molecular Testing Solution
Panther Scalable Solutions

Print article
AACC

Channels

Clinical Chem.

view channel
Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)

Plasma Amyloid-β 42/40 Assays Compared in Alzheimer Disease

Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of... Read more

Molecular Diagnostics

view channel
Image: The QuikRead go iFOBT is an immunochemical fecal immunochemical test for detection and quantification of human hemoglobin in feces in case of suspected bleeding from the lower gastrointestinal tract (Photo courtesy of Aidian)

Fecal Immunochemical Tubes Sourced to Analyze Gut Microbiome for CRC

Colorectal cancer (CRC) is a challenging public health problem which successful treatment depends on the stage at diagnosis. Recently, CRC-specific microbiome signatures have been proposed as a marker... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)

Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and... Read more

Immunology

view channel
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Biosciences)

Highly Multiplexed Cell Surface Protein Analyzed Via Flow Cytometry

Modern immunologic studies increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. One of the cornerstones... Read more

Pathology

view channel
Image: Characteristic bronchoalveolar lavage findings of diffuse alveolar hemorrhage (Photo courtesy of Peter C. Bauer, MD)

Bronchoalveolar Lavage Cell Pattern Determined for Diffuse Alveolar Hemorrhage

Diffuse alveolar hemorrhage (DAH) is a clinicopathological syndrome that describes the accumulation of intra-alveolar red blood cells originating from the alveolar capillaries. DAH can induce severe respiratory... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.